Processa Pharmaceuticals
PCSA
9 hedge funds and large institutions have $63.2K invested in Processa Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
13% more funds holding
Funds holding: 8 → 9 (+1)
0.02% more ownership
Funds ownership: 0.11% → 0.13% (+0.02%)
28% less capital invested
Capital invested by funds: $87.5K → $63.2K (-$24.3K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$33.7K |
| 2 |
VF
Virtu Financial
New York
|
+$26K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$7.5K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$15 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
-$28K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$4.73K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $20.7K | +$33.7K | +2,240 | New |
|
|
VF
2
Virtu Financial
New York
| $16K | +$26K | +1,729 | New |
|
|
3
Geode Capital Management
Boston,
Massachusetts
| $12.7K | +$7.5K | +498 | +57% |
|
4
Vanguard Group
Malvern,
Pennsylvania
| $9.04K | – | – | – |
|
|
MMA
5
Miracle Mile Advisors
Los Angeles,
California
| $3.7K | – | – | – |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $913 | +$15 | +1 | +1% |
|
7
Wells Fargo
San Francisco,
California
| $57 | – | – | – |
|
|
8
UBS Group
Zurich,
Switzerland
| $21 | -$4.73K | -314 | -99% |
|
9
Bank of America
Charlotte,
North Carolina
| $14 | – | – | – |
|
|
HF
10
HRT Financial
New York
| – | -$28K | -1,279 | Closed |
|
PCSA Hedge Fund Activity: Q1 2025 in Review
9 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Processa Pharmaceuticals (PCSA) for Q1 2025, worth a combined $63.2K — down 28% from $87.5K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new PCSA positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $33.7K. The largest seller was HRT Financial, exiting entirely with an estimated $28K sold.
- 9 institutional investors held Processa Pharmaceuticals (PCSA) as of Q1 2025, up from 8 in Q4 2024.
- Funds reported $63.2K of Processa Pharmaceuticals stock for Q1 2025, down 28% quarter-over-quarter.
- 2 funds opened new Processa Pharmaceuticals positions in Q1 2025 and 1 closed out, a net change of +1 holder.
- The largest Processa Pharmaceuticals buyer in Q1 2025 was Armistice Capital, an estimated $33.7K added.
- The largest Processa Pharmaceuticals seller in Q1 2025 was HRT Financial, an estimated $28K sold.
Based on aggregated 13F filings for Q1 2025.